Study highlights lack of transparency in FDA’s regulatory safety actions

Only about one-third of the US Food and Drug Administration’s (FDA) regulatory safety actions were supported by published studies and none were corroborated by public assessments from the Sentinel Initiative, according to a study of the agency’s adverse event reporting system.